Welcome to the Tivic Health Systems 2023 year-end shareholder update conference call. All participants will be in listen-only mode. Please note that the conference is being recorded. Statements made during this conference contain forward-looking statements about Tivic's business. You should not place undue reliance on forward-looking statements, as these statements are based upon management's current expectations, forecasts, and assumptions, and are subject to significant risk and uncertainties. These statements may be identified by words such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, continue, or the negative of these terms or other words or terms of similar meaning. Risks and uncertainties that could cause Tivic's actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in the company's annual report on Form 10-K for the year-ended December 31st, 2023, filed with the Securities and Exchange Commission on March 25th, 2024, as well as the company's subsequent filings with the SEC. Statements and information, including forward-looking statements, speak only to the date that they are provided unless an earlier date is indicated, and Tivic does not undertake any obligation to publicly update any statements or information, including forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Now let me hand over the call to Jennifer Ernst, Tivic Health's Chief Executive Officer. Hello everyone, and thank you for joining us today. I'm Jennifer Ernst, CEO of Tivic, and I'm joined today not only by our interim CFO, Kimberly Bambach, but also by our Chief Scientific Officer, Blake Gurfein. So before Kimberly Bambach goes over the details of the 2023 financial performance, I'd like to go through a few of the business developments for the year, and I'd like to have Blake Gurfein introduce the new area of vagus nerve research that we have been conducting with the Feinstein Institute for Bioelectronic Medicine. So let's start with looking at 2023. Over the past year, I have to say that our focus has been largely on the idea of stabilization and optimizing efficiency. No secret, the 2021 and 2022 were turbulent years not only for us but also for the industry as a whole, and a major focus for us has been on this stabilization and optimization. We started by stabilizing our supply chain after the significant disruptions and price fluctuations that we saw in 2022. We created new supply chain partnerships, and those have resulted in lower materials costs, lower assembly costs, and lower fulfillment costs. Those new partnerships are a critical component of increasing gross profitability of the business as a whole. In the Q1 of 2023, we also completed a 2,000-person marketing segmentation and pricing study. That study allowed us to take a very hard look at the areas where improvements were possible in the business. So in Q2, we undertook a price increase. That increase was nearly 50%, and I have to admit that that change negatively impacted the unit volume, and it did give us a temporary suppression in revenue. However, it is an important step that allowed us to then greatly improve our gross profit for 2023. Simultaneously, we reset and relaunched our advertising programs, improving efficiencies and our overall marketing spend. We established new distribution agreements with industry giants like most recently McKesson and their affiliate, Simply Medical, with Cardinal Health and Cencora, what we've formerly known as AmerisourceBergen. These distributors are targeting much less price-sensitive market segments. They're focused heavily on the healthcare industry, and we expect to see these relationships start to unlock new potential sales opportunities for the ClearUP product this coming year. We also, towards the end of the year, in collaboration with InStep Health, began to introduce the ClearUP device to over 2,500 healthcare providers and their patients. We saw particularly strong response, interestingly, among the general practitioners. Keeping in line with this idea of streamlining and optimization, we did decrease our headcount this year, better aligning the team size to the current scale of the ClearUP business. We streamlined operations with a very lean, focused team to minimize excess operating expenses. And like many other companies in the biotech and microcap space, we faced compliance issues with our NASDAQ listing this year. That placed tremendous pressure on the share price and forced the company into reverse stock split to regain compliance with the NASDAQ continued listing rules. That was taken care of in Q3, and now as I look at 2023, I can say we took the painful but necessary actions to bring our consumer health business to a point where I believe we can anticipate cash being generated from the ClearUP product sales. As I noted earlier, though, we took a hard look at where the business has been and where we see the strongest opportunities to build incrementally new value for our shareholders. In 2022, we conducted internal experimentation on a novel method of n on-invasive vagus nerve stimulation. The results indicated we could more precisely target and influence the activity of the vagus nerve in regulating biological functions than what had thus far been demonstrated in the state of the art. We saw this as an incredible opportunity for new value. With that lens, in 2023, we started building out our patent portfolio in VNS, where our prior patents and our current products have focused on the trigeminal nerve and sympathetic nerve structures. The new filing addresses a novel approach for non-invasive vagus nerve stimulation. You'll often hear this called VNS or NVNS. Our patent pending includes a new circuit design for more precise targeting of the signals that are carried by the vagus nerve, with the potential to offer superior efficacy to the alternative VNS approaches in market today. In Q3, we announced and began enrolling the first patients in our paid study at The Feinstein Institutes for Medical Research. We have recently announced the completion of patient enrollment, and I am very much looking forward and expecting to be reporting out on the results of that study in early Q2. So to set the context for those results and for what we have forthcoming, I've invited Blake Gurfein, our Chief Scientific Officer, to join us today in order to provide some additional context for this particular area of investment. So with that, let me hand this over to Blake Gurfein. Thank you, Jennifer Ernst. My name is Blake Gurfein, and I'm the CSO for Tivic Health. Since I have not previously presented on these calls, I will share some of my professional background. I'm a neuroscientist and immunologist and maintain an appointment as adjunct faculty in the Department of Neurosurgery at UC San Francisco. My work in the industry has focused on developing non-invasive neurotechnologies to stimulate the brain and peripheral nerves to treat a variety of conditions with limited therapeutic options. The ClearUP device was one of the technologies I had the privilege to help develop. As Jennifer Ernst mentioned, moving into the development of vagus nerve stimulation technology is very exciting and a promising direction for Tivic. The vagus nerve is an important target for clinical development because it's a key component of the autonomic nervous system, which controls cardiovascular activity, respiration, digestion, and many other critical functions in the body. Clinical use of vagus nerve stimulation has frequently employed implantable devices that require surgery. Vagus nerve stimulation has been proven effective for conditions including treatment-resistant depression, epilepsy, and migraine headache, and is currently being investigated to treat inflammatory diseases like rheumatoid arthritis and multiple sclerosis. There is a significant opportunity to develop safe and effective vagus nerve devices that can be applied non-invasively. Tivic has developed a proprietary non-invasive approach to vagus nerve stimulation based on our experience building evidence-based bioelectronic therapies. One of the key goals of this work is to more precisely target stimulation of the vagus nerve and more carefully control the types of physiologic effects that result from the stimulation. In collaboration with the Feinstein Institutes for Medical Research, a leader in vagus nerve research, we recently completed enrollment for a 20-person study evaluating the biological effects of our proprietary approach to vagus nerve stimulation. Analysis of the magnitude of the treatment effects and how they compare to clinically meaningful biological changes is an important stepping stone as we accelerate this program toward product development for large-market clinical use cases. I personally am looking forward to completing the study and sharing the results in the coming weeks. Now let me hand the call over to Kimberly Bambach to go over the 2023 financial results. Thanks, Blake Gurfein, and good afternoon, everyone. I am pleased to report the financial results for the year ending December 31st, 2023. Revenue, net of returns for the year-ended December 31st, 2023, was $1.2 million compared to $1.8 million for the year-ended December 31st, 2022. The decrease of $664,000, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average selling price per unit. Greater than 90% of our sales were direct to consumer in 2023. Returns, as a percentage of product revenue, was approximately 12% for the year-ended December 31st, 2023, and 10% for the year-ended December 31st, 2022. We expect, with the improved battery circuitry on ClearUP 2.0, that returns will decline. Cost of sales for the year-ended December 31st, 2023, was $889,000 compared to $1.5 million for the year-ended December 31st, 2022, a decrease of $652,000, or 42%. The decrease was due to the 52% decrease in overall unit sales, offset by $172,000 of costs related to the write-off or reserves on old inventory and components, primarily related to our ClearUP 1.0 unit, as the ClearUP 2.0 unit began shipping in December of 2023. We do not expect to incur similar costs in 2024. Therefore, gross profit for the year-ended December 31st, 2023, was $287,000 compared to a gross profit of $299,000 for the year-ended December 31st, 2022. Research and development expenses were $1.7 million for the year-ended December 31st, 2023, and December 31st, 2022. The emphasis of our research and development activities in 2023 was primarily related to our work with the Feinstein Institute. Activities in 2022 were primarily focused on product research and design in the migraine therapeutic area, initiation of a double-blind randomized controlled trial for postoperative pain relief following sinus surgery, and enhancement of our intellectual property protection. Sales and marketing expenses decreased to $2.1 million for the year-ended December 31st, 2023, compared to $2.8 million for the year- ended December 31st, 2022. The decrease was primarily due to the reduction of advertising and agency expenses. General and administrative expenses decreased to $4.8 million for the year- ended December 31st, 2023, compared to $5.9 million for the year-ended December 31st, 2022. The decrease is primarily due to a reduction in legal and professional fees and other corporate expenses as the company worked to reduce overhead costs. As a result, our 2023 full-year net loss was $8.2 million compared to $10.1 million in 2022. Regarding financing activity, on February 13, 2023, we sold shares of common stock, resulting in net proceeds of approximately $3.6 million. Further, from July 11th, 2023, to August 9th, we sold shares of common stock, resulting in a further aggregate net proceeds to the company of approximately $4.3 million. As of December 31st, 2023, the company had $3.4 million of cash and cash equivalents, and we continue to maintain a no-debt balance sheet. Further, on August 23rd, as Jennifer Ernst mentioned, we implemented a 1-for-100 reverse stock split, and on September 15th, we received confirmation from NASDAQ on our regaining compliance with the minimum bid price requirement. I will now hand the call back to Jennifer Ernst for ending remarks. Thank you, Kimberly Bambach. Thank you, Blake Gurfein, both for sharing your insights with our investor community. So this year, I think everyone is hearing, is one of resetting, rebuilding, and recovery. As part of our commitment to fiscal responsibility, we've decreased our expenses, we've reduced internal headcount, we've focused the team on profitably building the ClearUP product line, and at the same time, enhancing our R&D efforts to build new value for our shareholders. We revamped the administrative cost structure of the business. We reduced our overhead expenses. We've undertaken a more focused marketing and strategy, and we continue to see improvements in both gross and contribution margins. And as you've heard from me before, we continue to evaluate business combinations, licensing opportunities, both inbound, outbound, and M&A that may help to enrich our product portfolio with complementary offerings. We recognize, though, that those types of initiatives must be taken on, must be the right opportunities at the right time. We remain vigilant in assessing the opportunities that may provide significant, disproportionate benefit to our shareholders. Our research pipeline is beginning to mature, and it's becoming an even more important part of our strategy to build shareholder value. We believe that the VNS opportunity, as well as the medical extensions of our trigeminal nerve stimulation, have the potential to be of great significance to the company. 2023 involved hard decisions and very strict prioritization of spending. I am appreciative of our team and of the measures they have undertaken to control costs while continuing to improve the business performance. With that, I thank all of you for taking the time with us today. Look forward to speaking with you more as we make progress through the year and continue to report out on both the financial and research programs that you heard about today. Thank you to everyone, and we look forward to speaking with you at the next quarterly earnings call. This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.